Author response for "Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study"
2020 ◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽
